Anticipated $0.12 EPS for Simulations Plus, Inc. (SLP) on July, 9

June 27, 2018 - By Matthew Medley

Simulations Plus, Inc. (NASDAQ:SLP) Corporate Logo
During Q1 2018 the big money sentiment decreased to 1.5. That’s change of 0.06, from 2017Q4’s 1.56. 5 investors sold all, 21 reduced holdings as Simulations Plus, Inc. ratio worsened. 27 grew holdings while 12 funds bought holdings. Funds hold 5.63 million shares thus 2.37% more from 2017Q4’s 5.50 million shares.
Wedge Capital Management L Ltd Partnership Nc holds 45,500 shs. California Pub Employees Retirement Sys invested in 39,200 shs or 0% of the stock. 12,243 are held by Deutsche Bankshares Ag. Great West Life Assurance Can invested in 245 shs or 0% of the stock. Fincl Bank Of Montreal Can has 0% invested in Simulations Plus, Inc. (NASDAQ:SLP) for 8,280 shs. State Bank Of America Corporation De has invested 0% in Simulations Plus, Inc. (NASDAQ:SLP). Moreover, Federated Invsts Inc Pa has 0% invested in Simulations Plus, Inc. (NASDAQ:SLP). Crawford Invest Counsel Incorporated holds 0.18% or 387,614 shs. Macquarie Grp Ltd reported 4,081 shs. 475,216 were accumulated by Dimensional Fund Limited Partnership. Ranger Invest Management Limited Partnership holds 0.29% or 269,420 shs in its capital. Manufacturers Life The has invested 0% in Simulations Plus, Inc. (NASDAQ:SLP). Tower Research Limited Liability Com (Trc) holds 5,164 shs or 0.01% of its capital. The Ohio-based Bahl & Gaynor Incorporated has invested 0.01% in Simulations Plus, Inc. (NASDAQ:SLP). First Quadrant Lp Ca owns 0% invested in Simulations Plus, Inc. (NASDAQ:SLP) for 1,181 shs.

Simulations Plus, Inc. had 5 sales and 0 insider buys since February 26, 2018. This’s net activity of $1.29 million. KNEISEL JOHN ROBERT also sold $52,766 worth of Simulations Plus, Inc. (NASDAQ:SLP) on Friday, April 20.

On July, 9 Simulations Plus, Inc. (NASDAQ:SLP)’s earnings release is awaited by WallStreet, Faxor reports. This year’s EPS analyst estimate is awaited to be $0.12. That is 7.69 % down compareed to $0.13 EPS for last year. If $0.12 is reported, SLP’s profit will be $2.08 million for 49.48 P/E. Wall Street now forecasts 9.09 % EPS growth despite Simulations Plus, Inc. previous quarter’s EPS of $0.11. The stock increased 1.06% or $0.25 during the last trading session, touching $23.75.Simulations Plus, Inc. has 139,825 shares volume, 147.27% up from normal. SLP is uptrending and has moved 69.10% since June 27, 2017. SLP outperformed by 56.53% the S&P500.

Simulations Plus, Inc. develops and sells drug discovery and development software for mechanistic modeling and simulation.The company has $411.49 million market cap. The firm offers GastroPlus, which simulates the absorption, pharmacokinetics , and pharmacodynamics of drugs administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments, which measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments.50.42 is the P/E ratio. It also provides PKPlus, a standalone program that provides the functionality needed by pharmaceutical industry scientists to perform the analyses and generate the outputs needed to satisfy regulatory agency requirements for NCA and compartmental PK modelling; ADMET Predictor, a chemistry computer program, which takes molecular structures as inputs and predicts their properties; and MedChem Designer, a molecule drawing program or sketcher that integrates with MedChem Studio and ADMET Predictor.

Another two news for Simulations Plus, Inc. (NASDAQ:SLP) were recently released by: on June 26, 2018 with title “Simulations Plus (SLP) Names Shawn O’Connor as CEO”. The other‘s article was titled “Simulations Plus Names Shawn O’Connor as CEO” and released on June 26, 2018.

Simulations Plus, Inc. (NASDAQ:SLP) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.